Combination chemotherapy with carboplatin, docetaxel, and gemcitabine in advanced non-small-cell lung cancer: A phase II study

Journal of Clinical Oncology

Volumn 17, Issue 12, 1999, Pages 3816-3821

  Pectasides, D ^a   Aspropotamitis, A ^a   Halikia, A ^a   Visvikis, A ^a   Antoniou, F ^a   Kalantaridou, A ^a   Karvounis, N ^a   Batzios, S ^a   Athanassiou, A ^a  

^a METAXA CANCER HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DOCETAXEL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; EDEMA; FEMALE; FLUID RETENTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032761165     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1999.17.12.3816     Document Type: Article

References (43)

1. Bakowski MT, Couch JC: Chemotherapy for non-small cell lung cancer: A reappraisal and look to the future. Cancer Treat Rev 10:159-172, 1983
2. Finkelstein DM, Ettinger DS, Ruckdeschel JC: Long-term survival in metastatic non-small cell lung cancer: An Eastern Cooperative Oncology Group Study. J Clin Oncol 4:701-709, 1986
3. Abratt RP, Bezwoda WR, Falkson G, et al: Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: A phase II study. J Clin Oncol 12:1535-1540, 1994
4. Anderson H, Lund B, Bach F, et al: Single agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 12:1821-1826, 1994
5. Fossella FV, Lippman SM, Tarassof P, et al: Phase I/II study of gemcitabine, an active agent for advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 14:371, 1995 (abstr 1144)
6. Gatzemeier U, Shepherd FA, Le Chevalier T, et al: Activity of gemcitabine in patients with non-small cell lung cancer: A multicenter, extended phase II study. Eur J Cancer 32:243-248, 1996
7. Fossella FV, Lee JS, Murphy WK, et al: Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 12:1238-1244, 1994
8. Francis PA, Rigas JR, Kris MG, et al: Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 12:1232-1237, 1994
9. Bums HA, Eckardt J, Fiedls S, et al: Phase II trials of Taxotere in patients with non-small-cell lung cancer. Proc Am Soc Clin Oncol 12:364, 1993 (abstr 1116)
10. Cerny T, Kaplan S, Pavlidis N, et al: Docetaxel (Taxotere) is active in non-small cell lung cancer: A phase II trial of the EORTC early clinical trials groups (ECTG). Br J Cancer 70:384-387, 1994
11. 2 with prednisone premedication in non-small-cell lung cancer. Proc Am Soc Clin Oncol 13:364, 1994 (abstr 1226)
12. Bonomi PD, Finkelstein DM. Ruckdesche JC, et al: Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV NSCLC: A study of the ECOG. J Clin Oncol 7:1602-1613, 1989
13. Klastersky J, Sculier JP, Lacroix A, et al: A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer protocol 17871. J Clin Oncol 8:1556-1562, 1990
14. Kaye SB: Gemcitabine: Current status of phase I and II trials. J Clin Oncol 12:1527-1531, 1994
15. Peters GJ, Bergman AM, Ruiz van Haperen VWT, et al: Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22:72-79. 1995 (suppl 11)
16. Peters GJ, Ruiz van Haperen VWT, Bergman AM, et al: Preclinical combination therapy with gemcitabine and mechanism of resistance. Semin Oncol 23:16-24, 1996 (suppl 10)
17. Sandier AB, Ansari R, McClean J, et al: A Hoosier Oncology Group phase II study of gemcitabine plus cisplatin in non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 14:357, 1995 (abstr 1089)
18. Crino L, Scagliotti G, Marangolo M, et al: Cisplatin-gemcitabine combination in non-small-cell lung cancer (NSCLC): A phase II Study. J Clin Oncol 15:297-303, 1997
19. Abratt RP, Bezwoda WR, Goedhals L, et al: Weekly gemcitabine with monthly cisplatin: Effective chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 15:744-749, 1997
20. Steward WP, Dunlop DJ, Dabouis G, et al: Phase I/II study of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: Preliminary results. Semin Oncol 23:43-47, 1996 (suppl 10)
21. Anton A, Artal A, Carrato A, et al: Gemcitabine plus cisplatin in advanced NSCLC: Final phase II results. Proc Am Soc Clin Oncol 16:461, 1997 (abstr 1656)
22. Shepherd F, Cormier Y, Burkes R, et al: Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer. Semin Oncol 24:27-30, 1997 (suppl 8)
23. Carmichael J, Allerheiligen S, Walling J: A phase I study of gemcitabine and carboplatin in non-small-cell lung cancer (NSCLC). Semin Oncol 23:55-59, 1996 (suppl 10)
24. Carmichael J, Langley R, Osbourne L, et al: A phase I study to investigate alternate sequencing of the combination gemcitabine followed by carboplatin in NSCLC. Eur J Cancer 33:230, 1997 (suppl 8) (abstr 1042)
25. Gueritte-Voegelein F, Guenard D, Lowelle F, et al: Relationships between the structure of taxol analogues and their antitumour activity. J Med Chem 34:992-998, 1991
26. Ringel I, Orwitz SB: Studies with PR-56976 (Taxotere): A semi-synthetic analogue of Taxol. J Natl Cancer Inst 83:288-291, 1991
27. Fossela FV, Lee JJ, Bertile J, et al: Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second line treatment of advanced non-small cell lung cancer. Semin Oncol 22:22-29, 1995 (suppl 4)
28. Cole JT, Gralla RJ, Marques CB, et al: Phase I-II study of cisplatin + docetaxel (Taxotere) in non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 14:357, 1995 (abstr 1087)
29. Zalcberg JR, Bishop JF, Millward MJ, et al: Interim results of a phase II trial of docetaxel in combination with cisplatin in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC). Eur J Cancer 31A:1084, 1995(suppl 5)
30. Monnier A, Douillard JY, Belli L, et al: Interim analysis of a phase II study of docetaxel (Taxotere) and cisplatin in advanced non-small cell lung cancer. Presented at the sixth International Congress on Anti-Cancer Treatment, Paris, France, February 6-9, 1996
31. Androulakis N, Kourousis C, Kakolyris S, et al: First line treatment of non-small cell lung cancer with docetaxel and cisplatin: Preliminary results of a phase II study. Ann Oncol 7:98-99, 1996 (abstr 4689)
32. Mattson K, Saarinen A, Jekunen A: Combination treatment with docetaxel (taxotere) and platinum compounds for non-small-cell lung cancer. Semin Oncol 24:5-8, 1997 (suppl 14)
33. Beahrs OH, Henson DE, Hutter RVP: Manual for Staging of Cancer (ed 4). Philadelphia, PA, JB Lippincott, 1992
34. Calvert AH, Newell DR, Gumbrell LA: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
35. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment [WHO Offest Publication No. 48]. Geneva, Switzerland, World Health Organization, 1979
36. Kaplan EL, Meier P: Non-parametric estimation for incomplete observations. J Am Stat Assoc 53:457-481, 1958
37. Georgoulias V, Kourousis CH, Androulakis N, et al: Docetaxel (Taxotere) and gemcitabine in the treatment of non-small cell lung cancer: Preliminary results. Semin Oncol 24:22-25, 1997 (suppl 14)
38. Langer CJ, Calvert P, Ozols RF: Gemcitabine and carboplatin in combination: Phase I and phase II studies. Semin Oncol 25:51-54, 1998 (suppl 9)
39. Zalcberg J, Millward M, Bishop J, et al: Phase II Study of docetaxel and cisplatin in advanced non-small-cell lung cancer. J Clin Oncol 16:1948-1953, 1998
40. Kosmidis PA, Mylonakis N, Fountzilas G, et al: Paclitaxel and carboplatin in inoperable non-small-cell lung cancer. Ann Oncol 8:697-699, 1997
41. Dombernowsky P, Giaccone G, Sandler A, et al: Gemcitabine and paclitaxel combinations in non-small-cell lung cancer. Semin Oncol 25:44-50, 1998 (suppl 9)
42. Georgoulias V, Kourousis C, Kakolyris S, et al: Second-line treatment of advanced non-small cell lung cancer with paclitaxel and gemcitabine: A preliminary report on an active regimen. Semin Oncol 24:61-66, 1997 (suppl 12)
43. Georgoulias V, Kourousis C, Androulakis N, et al: Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: A multicenter phase II trial. J Clin Oncol 17:914-920, 1999